Search Press releases Keywords From To 24 Jun 2005 FDA Approves UCB's Keppra® for Use in Childhood Epilepsy Read More 14 Jun 2005 UCB Confirms Positive Financial Outlook for 2005 Read More 13 May 2005 UCB and Lonza Enter Into a Strategic Bio-Manufacturing Alliance Read More 19 Apr 2005 UCB Confirms Strong Quarterly Sales In The Us Xyzal Sells More Than Zyrtec In Europe Read More 18 Apr 2005 UCB Announces European Launch Of Kentera(TM) The First European Transdermal Oxybutynin Treatment For Overactive Bladder Read More 31 Mar 2005 First evidence of efficacy for UCB's Keppra®* in the adjunctive treatment of myoclonic seizures Read More Pagination First page Previous page Previous … Page 191 Page 192 Page 193 Page 194 Current page 195 Page 196 Page 197 Page 198 Page 199 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
